- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals , Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare

PALO ALTO, Calif. , July 7, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President

- Lambda is administered as a one-time, outpatient, subcutaneous dose PALO ALTO, Calif. , July 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare